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THE ACTIVATION OF DOPAMINERGIC NEURONAL GROUPS 
By 
Remington J Rice  
 This study corroborates with evidence that increased activity in dopamine 
pathways can cause hyperactive locomotion and other behaviors related to psychosis. 
However, the involvement of these specific cell types in schizophrenia is not fully 
understood. The psychostimulant amphetamine is one of the numerous compounds that 
can alter dopamine concentrations all over the brain, leading to psychotic effects in 
healthy humans. Administration of amphetamine to experimental animals has been used 
to create models of schizophrenia; producing a unique array of behavioral effects, such as 
hyper-locomotion and a collection of behaviors referred to as stereotypy. In contrast, 
certain antipsychotic drugs that act directly upon dopaminergic neurons have been shown 
to alleviate schizophrenic symptoms. Three weeks after the infusion of an adeno-
associated viral vector into transgenic TH: Cre Sprague Dawley rats, a light sensitive 
channel, will be expressed on dopaminergic neurons. Depolarization of the neuron 
rapidly occurs after pulses of 465 nm wavelengths of light, blue light, are sent through a 
fiber optic cable to the injection site. These dopaminergic cells exist in relatively high 
concentrations throughout multiple brain regions. Optogenetic tools have been used to 
selectively activate dopaminergic neurons in the ventral tegmental area (ventral tegmental 
area) during behavioral assessment sessions. These findings validate past ideals about the 
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Schizophrenia is a mental disorder that encompasses a wide range of behavioral 
patterns that can result in a severely reduced ability to function in everyday life. Since its 
first description in the mid to late 1800s, the numerous life-altering symptoms have been 
cataloged. However, the causes of these symptoms are incompletely understood. 
Advancements in research techniques and pharmaceutical compounds have enhanced 
humanity’s understanding of how the mental disorder affects the brain. The continuing 
toil from scientists around the world will continue to decrease the suffering in patients 
diagnosed with schizophrenia	(Frith,	1987;	Friston,	1992;	Knapp,	2004;	Shenton,	
2001). 
 The term itself is a product from the Greek roots skhizein “to split” and phrën 
“mind” (Kuhn & Cahn, 2004). Eugen Bleuler first used the term during a lecture in 
Berlin on April 24th, 1908. In 1911, Bleular expanded on schizophrenia in his seminal 
study Dementia Praecox, oder Gruppe der Schizophrenien (Dementia Praecox, or the 
Group of Schizophrenias). It would be another 40 years until it was translated into 
English. During this time, the ideas tested by Emil Kraepelin and Kurt Schneider also 
added into the modern sense of the word (Andreasen, 1989). All three of these 
researchers heavily influenced the definition of schizophrenia described by the American 
Psychiatric Association in the Diagnostic and Statistical Manual (DSM-III).  
 The latest edition of the manual (DSM-V), carries over six different criteria (A-F) 
from previous editions, to assist in the evaluation of patients. Typically, a diagnosis is 
given when two symptoms from criteria A and at least one other are present for a 
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significant amount of time (Tandon et al., 2013). Characteristic symptoms of 
schizophrenia (Criterion A), are divided into positive and negative symptoms. Positive 
symptoms are feelings or behaviors that are not usually present. The list of positive 
symptoms includes delusions, hallucinations, disorganized speech, grossly disorganized, 
and catatonic behavior. Negative symptoms are a lack of feelings or behaviors. Examples 
of this include affective flattening, anhedonia, and alogia (American Psychiatric 
Association, 2013). The DSM V continues and describes criterion B as social/ 
occupational dysfunctional. A duration of symptoms with no change for 6 months defines 
criterion C. The remaining criteria are meant to exclude other explanations for the 
symptoms. Criteria D-F attempt to ensure that the patient is not suffering from a mood 
disorder, substance abuse, and/or autism spectrum disorder.  
 Schizophrenia occurs in about 7 people per 1000 (Saha, Chant, Welham, & 
McGrath, 2005). A 2004 cost-of-illness study analyzed 62 peer-reviewed articles in an 
attempt to calculate the societal burden of schizophrenia. The researchers summed up 
direct, indirect, and intangible costs. Direct costs include payments made for various 
therapies and treatments. When a disorder causes an individual to not be able to work in 
society, it is categorized as an indirect cost; in other words, a resource is lost. The 
intangible costs are described as pain or depression. Knapp (2004) collected past 
estimates of cost and demonstrated that in the year 1990, this mental disorder put a $65 
billion burden on the United States economy. 
 The societal costs of schizophrenia are severe, in part due to reduced life 
expectancy for patients. The life expectancy for men with schizophrenia is below the 
national average by 14.6 years (Chang et al., 2011). Chang et al. (2011) explained that the 
impact of this serious mental illness on life expectancy is significant and commonly 
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higher than the corresponding impact of well-recognized adverse exposures such as 
smoking, diabetes and obesity. Strategies to isolate and prevent causes of premature death 
are urgently necessary. 
In addition to a higher rate of suicide, 15% of patients also suffer from Type II 
diabetes (Dixon et al., 2000). Dixon et al. (2000) demonstrated that this is significantly 
higher than the national average and the patients’ health suffered in other areas; such as 
decreased life satisfaction and an overall diminished quality of life. However, these 
authors commented that 87% of the patients in the study were prescribed antipsychotic 
compounds. This made determining if the poor health observed was due to the mental 
illness or medication, the latter has been shown to have a host of adverse effects 
(described below). 
 The causes of schizophrenia are unknown. Research has produced evidence that 
environmental variables, brain structure, and genetic components factor into the complex 
issue. Environmental factors such as drug use and prenatal stressors have all been 
correlated with a portion of schizophrenic patients (Picchioni & Murray, 2007). In 
addition to that premise, magnetic resonance imaging (MRI) studies have shown less 
grey matter volume in the frontal cortex and temporal lobes (Hirayasu et al., 1998). There 
is a 1% prevalence in the general population and near 50% for monozygotic twins or 
having two biological parents with schizophrenia  
(DiLalla & Gottesman, 1991). Finally, the increased odds of diagnosis between relatives 
that have never met, shows that there is a strong heritability factor in the mental illness 
(Kendler & Diehl, 1993). Many of the numerous potential causes have also been 
connected with specific neurotransmission abnormalities. One of the theories put forth to 
describe the causal mechanisms of schizophrenia is the dopamine hypothesis. 
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The Dopamine Hypothesis of Schizophrenia 
 
In regard to proposals put forth to explain what dysfunctional mechanisms are 
causing schizophrenia, the dopamine hypothesis has been one of the most prevailing. The 
earliest versions of this hypothesis proposed that dopamine producing neurons in the 
brain were hyperactive, leading to increased extracellular levels of dopamine (Meltzer & 
Stahl, 1976, Haracz, 1982). The dopamine hypothesis was put forth after the discovery of 
antipsychotic drugs and the observations that they could relieve some psychotic 
symptoms (Delay, Deniker, & Harl, 1952). It was found that some of these drugs 
accelerated the breakdown of dopamine in the brain (Carlsson & Lindqvist, 1963). In 
addition to that, other compounds, namely reserpine, was also effective in treating 
psychosis and it was discovered that it blocks the storage of monoamine vesicles and 
essentially depletes dopamine in neurons (Carlsson, Lindqvist, & Magnusson, 1957). The 
dopamine enhancing drug levodopa, which is used to treat Parkinson’s disease 
symptoms, can also cause psychotic side effects similar to schizophrenia (Seaman,	
1998).  
Illicit substances such as amphetamine and cocaine increase dopamine release and 
prevent recycling of the neurotransmitter in the synapse; this action has been shown to 
induce psychotic symptoms (Lieberman, Kane, & Alvir, 1987). Lieberman discovered 
that “amphetamine psychosis” is, in part due to an increase of synaptic monoamine 
levels. With this evidence, the first version of the dopamine hypothesis put forth the idea 
that increased dopamine levels would cause schizophrenia-like positive symptoms.  
 Later in the 20th century, a modified dopamine hypothesis of schizophrenia was 
introduced (Davis, 1991). By this time, imaging data had narrowed down the effects into 
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specific regions. Evidence that the overactive neurons may be a mechanism of the 
disorder, comes from positron emission tomography data (Friston, Liddle, Frith, Hirsch, 
& Frackowiak, 1992). In 30 schizophrenic patients, a significant portion of the patients 
had increased regional cerebral blood flow in left medial temporal region, mesencephalic, 
thalamic and left striatal structures; with the highest concentration in the left 
parahippocampal region. Similar MRI studies have confirmed the intense neuron activity 
(Shenton, Dickey, Frumin, & McCarley, 2001). 
Neuroimaging studies also support the dopamine hypothesis for schizophrenia. 
Lim et al. (2012) confirmed dopamine type 2 (D2) receptor antagonists produce reduced 
activity in some of the aforementioned areas. Eight male volunteers were given oral doses 
of haloperidol once daily for seven days. Comparisons of PET scans before and after 
treatment indicated more D2 receptor blockage with treatment. This knowledge has been 














Dopaminergic Pathways of the Brain 
 
 Dopamine is released in the brain by neurons in the central nervous system and 
functions as a neurotransmitter. Dopamine is a monoamine neurotransmitter, meaning 
that it contains a single “amine” molecule. Amines are comprised of a basic nitrogen 
atom with a pair of non-binding valence electrons. Dopamine is an amine derived from 
the decarboxylation of L-DOPA. A widespread diversity of physiological function is 
mediated by the D1, D2, D3, D4, and D5 G-protein couple receptors (Beaulieu et al., 2015). 
Beaulieu’s (2015) review of dopamine receptor literature shows that dopamine receptor 
actions extend past the action of cAMP signaling and influences numerous other cellular 
responses, such as receptor desensitization. 
 Dopamine has been strongly implicated in the numerous physiological functions, 
including the control of body temperature (Chaperon et al., 2003). Chaperon (2003) 
demonstrated that a selective D1 antagonist SCH 23390 and selective D2 antagonist L-
741,626 would elicit hypothermia in experimental rats. Other research conducted with D3 
knock-out rats demonstrated the same hypothermia as well as decreased locomotion 
(Boulay, 1999). Other physiological functions will be described below, in conjunction 
with the individual dopaminergic pathways responsible. 
There are four major dopamine pathways in the human brain. The mesolimbic, 




Figure 1. The ventral tegmental area has dopaminergic projections to the frontal 
cortex (prefrontal cortex and other frontal lobe regions), the nucleus accumbens, the 




Current electrophysiological techniques have been challenged in discerning which 
ventral tegmental area dopamine neurons project to the nucleus accumbens (and 
elsewhere in the limbic system) or the prefrontal cortex (PFC). However, dual-probe 
micro dialysis has been more enlightening about the nature of these neurons (Westerink, 
Kwint, & deVries, 1996. German & Manaye, 1993). Researchers discovered that less 
than 10% of the A10 (the identification of the ventral tegmental area in rats) dopamine 
neurons project to the PFC. Florescent staining has confirmed this hypothesis as well. 
Multiple fluorescent staining procedures have demonstrated that the projections to the 
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nucleus accumbens could account for up to 80% of dopaminergic neurons (Swanson, 
1982). However, a wide diversity of neurons exists along with dopaminergic neurons. 
Both glutamatergic neurons (Yamaguchi et al., 2007) and GABAergic neurons (Carr & 
Sesack, 2000) exist and communicate with dopaminergic projections. 
 As noted earlier, the mesolimbic pathway has been shown to produce the 
“positive” symptoms of schizophrenia (Gray et al., 1995). Gray (1995) demonstrated that 
excess dopamine from the mesolimbic pathway contributes to difficulties in processing 
incoming stimuli. The researcher reviewed studies that disrupted this pathway in animal 
models with either surgical damage or systemic drug delivery and tested them with a 
behavioral paradigm called latent inhibition. “Negative” symptoms such as reduced 
emotional responsiveness (affective blunting) or social withdrawal has been connected to 
diminished mesocortical pathway activity (Meltzer & Stahl, 1976; Gold et al., 2013). 
Antipsychotic drug effects in the nigrostriatal pathway have been implicated in being 
responsible for a type of drug-induced movement dysfunctions known as extrapyramidal 
symptoms (Pierre, 2012). Finally, the tuberoinfundibular pathway is a group of dopamine 
neurons that regulate the secretion of prolactin from the anterior pituitary gland 
(described further below). 
The “meso” prefix means “middle” in Greek, and refers to the midbrain or 
“middle brain.” The mesolimbic and mesocortical pathways both stem from midbrain 
regions, specifically the ventral tegmental area. This brain region overlaps in both 
pathways, but there are distinct differences between the two. The differences can be 
simply ascertained from looking at where the ventral tegmental area projects too. The 
mesolimbic pathway consists of mid brain regions connected to the limbic system and the 
mesocortical consists of midbrain regions communicating with the cerebral cortex.  
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The largest group of dopaminergic neurons in the mesolimbic pathway stems 
from the ventral tegmental area through the medial forebrain bundle to the nucleus 
accumbens (German & Manaye, 1993). The ventral tegmental area also communicates 
with the basal lateral amygdala in this pathway.  The nucleus accumbens plays a major 
role in pleasure, reward, motivation, and reinforcement learning (Wenzel, Rauscher, 
Cheer, & Oleson, 2015). Wenzel (2015) found that dopamine signaling from the ventral 
tegmental area influences motivated behavior and response to environmental stimuli. The 
group of researchers used fast-scan cyclic voltammetry to show real-time increases in 
nucleus accumbens dopamine concentrations when animals were presented with 
predictors of aversion and its avoidance. This evidence clearly shows that dopamine 
activity in the nucleus accumbens plays a role in moderating positive and negative stimuli 
during adaptive behaviors. He continues and states that the nucleus accumbens is 
composed of medium spiny neurons. Along with the dopaminergic neuronal projections 
from the ventral tegmental area, the nucleus accumbens receives input from 
glutamatergic neurons in the amygdala, hippocampus, and medial prefrontal cortex.  
The mesocortical pathway connects the ventral tegmental area to the prefrontal 
cortex.  The prefrontal cortex carries out executive functions such as regulating voluntary 
movement and planning for actions and is essential for working memory. These functions 
have been strongly linked to the prefrontal cortex by analyzing deficits during various 
behavioral paradigms such as the radial-arm maze, water maze, and attention tasks after 
experimental animals received lesions or injections of excitotoxin (Romanides, et al., 
1999; Sakurai & Sugimoto, 1985; Viggiano, et al., 2002).  
Recent fMRI experiments with healthy humans have shown neuronal activity to 
increase in the PFC during periods of manic like behaviors (Passamonti et al., 2015). 
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These behaviors have been linked to disorders associated with dopamine dysfunction 
(Post, Jimerson, Bunney, & Goodwin, 1980). fMRI data in human beings collected by 
Passamonti et al. (2015) has validated that this critical component of the prefrontal 
cortex, is responsible for certain behaviors attributed with dopamine function. However, 
fMRI results lack the specificity to determine exactly what cell types were active in those 
areas.  
Specific gene mutations that produce abnormal protein function in the 
mesocoritcal pathway has been implicated in schizophrenia. A recent study has shown 
that abnormal gene activity in the frontal lobe, specifically a functional polymorphism of 
the Val and Catechol-O-methyltransferase (COMT) gene, can slightly increase risk for 
schizophrenia (Egan et al., 2001). COMT is an enzyme that breaks down dopamine. The 
researchers state that high activity of the COMT and Val alleles can compromise the 
postsynaptic impact of dopamine response in the frontal cortex.  
Furthermore, evidence is now demonstrating how both the mesolimbic and 
mesocortical pathways communicate with each other (Laviolette, 2007). The image 
below details how dysfunction in the pathways can give rise to symptoms of 
schizophrenia. Laviolette (2007) makes it apparent that dysfunction of dopamine from the 
ventral tegmental area plays a role with functions necessary for every day behaviors, such 





Figure 2. When dopamine production in the ventral tegmental area is 
dysregulated, this can have varying effects in multiple brain regions that are held 
responsible for schizophrenic symptoms. The large arrows represent forward 
dopaminergic projections that exist in the mesolimbic and neocortical pathways. The 
small arrows represent feedback loops that exist in both pathways. This image 
demonstrates that each pathway is intimately involved with each other. See the main text 
for descriptions of specific regions and paths involved with individual pathway. 
 
The nigrostriatal pathway is mostly involved in the production of movement and 
loss of these dopamine neurons is one of the foremost pathological features of 
Parkinson’s disease (Diaz, 1996). As noted earlier, antipsychotic compounds have been 
shown to induce extrapyramidal side effects (EPS) in patients with schizophrenia. EPS 
are drug induced movement disorders that include tardive dyskinesia, rigidity, and 
restlessness. These symptoms are typically caused by antipsychotic drugs that antagonize 
dopamine D2 receptors (Pierre, 2005). This notion will be explored further in latter 
portions of this document. 
12	
	
The last major dopamine pathway, the tuberoinfundibular pathway, is important 
for the regulation of the release of prolactin. Prolactin is a luteotropic hormone that 
enables mammals to produce milk and is involved in a large number of other hormonal 
processes. The entire dissection of this endocrinology topic is outside the scope of this 
document. However, it is important to note that the tuberoinfundibular pathway may not 
be linked to the symptoms of schizophrenia, but antipsychotic drugs definitely exert 
effects here (Clemens, Smalstig, & Sawyer, 1974). Clemens (1974) produced evidence 
that prolactin concentrations increased after the administration of dopamine antagonizing 
antipsychotic drugs. This excess of prolactin levels can cause hyperprolactinemia, which 
can include infertility, loss of libido, erectile dysfunction, hypoestrogenism, and other life 
















Pharmacotherapy for Schizophrenia 
 
Beginning in the 1950s, the scientific community has been gaining substantial 
amounts of knowledge about which neurotransmitters are associated in schizophrenia. In 
part, due to the development of selective drugs that allowed researchers to infer which 
neurotransmitters are involved in schizophrenia. The development of compounds used to 
treat Parkinson’s disease and the development of classical antipsychotic drugs advanced 
our understanding which neurotransmitters are involved with schizophrenic symptoms. 
Dopamine replacement therapy has helped patients with Parkinson’s disease gain some of 
their motor function loss (Hornykiewicz et al., 1973). This therapy includes 
administration of a precursor to dopamine, L-DOPA, and it effectively increases 
dopamine concentrations. In contrast, some of the first antipsychotic drugs developed 
have induced deficits in motor function similar to the motor symptoms of Parkinson’s 
disease, which again is referred to as extra pyramidal symptoms. The first drugs that 
caused this motor dysfunction, primarily chlorpromazine and haloperidol, are now 
classified as “typical,” “classical,” or “first-generation” antipsychotic drugs; referred to as 
typical antipsychotics for this document. Along with these side effects, these drugs 
alleviate the positive symptoms of schizophrenia by blocking dopamine receptors	
(Seaman, 1975) (Crow, 1980). As mentioned before, the decrease of dopamine and 
decrease of psychotic symptoms caused by antipsychotic drugs, led to the concept that an 
increase of dopamine activity caused psychosis. This was essential to the foundation of 
the dopamine hypothesis of schizophrenia. 
Since the development of the first antipsychotic drugs, new compounds have been 
manufactured that produce a lower risk of extra pyramidal symptoms at therapeutically-
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effective doses (Pierre, 2012). These are known as second generation antipsychotics, also 
referred to as “atypical” or “novel” antipsychotic drugs. Atypical antipsychotics can still 
produce other severe side effects as well including tardive dyskinesia (involuntary 
repetitive body movements) and neuroleptic malignant syndrome (muscle rigidity, fever, 
and cognitive deficits).  
The World Health Organization (WHO) recommends the administration of 
atypical antipsychotics as first line treatments for patients with schizophrenia. The effects 
and reduction of symptoms may take as long as 6-8 weeks (Emsley et al., 2006). There 
are several health organizations that offer a schematic and information to provide the 
optimal drug administration in varying conditions (Taylor, Paton, & Kapur, 2015).  
It is important to note at this time that most, if not all, antipsychotic drugs exert 
effects on several different types of receptors and neurons all over the brain. However, 
every antipsychotic drug does bind to D2 receptors, with the exception of one that is 
claimed to be a partial agonist (aripiprazole). All other typical antipsychotic drugs are D2 
antagonists and the typical antipsychotic drug haloperidol, like many others. also has a 
binding affinity for noradrenergic and serotonin receptors (Schotte, Janssen, Megens, & 
Leysen, 1993). Schotte (1993) put forth that the antagonism of the serotonin receptor 5-
HT2A could contribute to haloperidol’s reduction of hallucinations, delusions, and other 
positive symptoms of schizophrenia. However, most atypical antipsychotic drugs have 
greater affinity the antagonism of 5-HT2A receptors than D2 receptors (Meltzer, 1989; 
Schotte et al., 1996). These series of experiments have made it clear that dopamine 
receptors are important, but are not the only component involved with schizophrenia. 
Diminished levels of glutamate release in the same areas that dopamine pathways 
communicate with may also cause symptoms of schizophrenia (Paz, Tardito, Atzori, & 
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Tseng, 2008). Elevated concentrations of dopamine, has been shown to worsen positive 
symptoms of schizophrenia (Laruelle et al., 1996). Laruelle (1996) administered 
amphetamine to drug-free patients with schizophrenia and collected computerized 
tomography data that detailed striatal dopamine release. Their data indicates that 
schizophrenic patients had more D2 occupancy after amphetamine administration, when 
compared to healthy individuals. This would imply that the patient’s neurons were 
hypersensitive to dopamine. The dopamine hypothesis and other evidence provides a 
better understanding of the mental illness. However, there is still important questions to 
be answered within each individual hypothesis.  
Animal models of schizophrenia have been vital in gaining knowledge to help 
patients. It has been demonstrated that the dopamine antagonist raclopride, when co-
administered with other antipsychotic drugs, can increase the dopamine concentrations in 
the medial prefrontal cortex (Westerink et al., 2001, Farde et al., 1992).  This synergism 
of drugs is meant to reduce psychotic symptoms. Farde (1992) used D2 radioligands and 
positron emission tomography (PET) to determine that raclopride quickly occupies D2 
receptors in the basal ganglia. The basal ganglia is mainly comprised of dopaminergic 
neurons that synapse onto gamma–Aminobutyric acid (GABA) producing neurons 










Francis Crick articulated in 1979 that in order to better understand the brain, 
scientists would need to be able to control specific types of cells or individual neurons 
(Crick, 1979). He stated that if this were possible, one could activate a single neuron and 
watch the cascade of other neurons being activated. Or, alternatively, inhibit a neuron and 
see what other cells around it followed. Crick continues and believed that this would 
someday be possible. His knowledge of the visual system, a system of the brain that 
responds to light, may have led to his thoughts that we could control specific types of 
neurons in any part of the brain.  
It is now possible to control specific cell types with high temporal and spatial 
precision in the central nervous system (CNS) of mammals. In the past, electrical 
stimulation has been able to target areas of the brain with temporal precision, but was not 
cell specific; electric current will stimulate every type of cell in the area of effect (You, 
1998). Drug research in the past has been able to target specific types of cells, but lacks 
the ability to target specific areas. An example of a drug exhibiting these characteristics is 
haloperidol. Haloperidol blocks dopamine transmission on D2 receptors located on many 
different types of neurons throughout the brain (Seeman, 2002). The modern procedure 
described in the coming pages, optogenetics, attempts to overcomes both of these 
obstacles.  
 The development of optogenetics was cultivated from several different fields of 
science. The microbial opsins involved in optogenetics are similar to the photoreceptor 
cells produced in the human eye. Photoreceptor cells contain a pigment called retinal, 
which transforms electromagnetic radiation (light) into electrical signals that are sent 
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further into the brain for processing. A photon of light is captured and causes 
isomerization of retinal; an alteration in the molecular structure initiating the surge of 
information. Using the technology of optogenetics, it is possible to induce expression of 
similar photoreceptors onto targeted neurons in the brain, creating neurons that are 
sensitive to light (Deisseroth, 2011).  
 However, humans are not the only species to have evolved machinery to sense 
electromagnetic energy in their setting. For example, channelrhodopsin-2 (ChR2) is a 
light-gated ion channel present in green algae Chlamydomonas reinhardtii (Nagel, 2003). 
Unicellular green alga uses these photoreceptors to orient themselves in response to 
sunlight. The photoreceptors belong to a family of rhodopsins that function as a channel 
by absorbing a photon of light to create permeability for monovalent and divalent cations. 
Researchers discovered the ChR channel in 1971 (Foster, 1980). Not until three and a 
half decades later was the potential of this biological machine brought to light. 
 In 2005, Karl Deisseroth and Ed Boyden discovered a way to make mammalian 
hippocampal cells sensitive to light through implantation of ChR2 (Boyden, 2011). 
Shining blue light (473 nm wavelength photons) on these cells in vitro would cause them 
to send nerve impulses 1-2 milliseconds later. Once the light was turned off, the cells 
returned to normalcy. In their resting state, an electrical potential exists between the 
interior of the cell and outside of the cell. When ChR2 was activated, its channel would 
open and cause an influx of positive ions, acting to increase the internal cellular charge 
and cause cellular depolarization. This process of neurons changing their electrical charge 
and sending action potentials is a similar to the normal electrical communication that 
occurs all over the brain during every emotion, action, and sensory input we perceive.   
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 In order to produce ChR2 in a mammalian brain, the genetic codes for the light 
sensitive protein must be injected into each neuron with the help of a vector. The primary 
vectors used in optogenetics, the adeno-associated viruses (AAVs), were discovered in 
the 1960s. AAVs are infectious and non-pathogenic and have been used in various other 
gene therapy techniques.  
 Another vital piece of the optogenetics puzzle is the light source. ChR2 is 
activated about 1 mW of blue light, ~470 nm wavelengths (Lin, 2011). Diode-pumped 
solid-state lasers have been the prevalent equipment to activate ChR2. Lasers can output 
thousands of mWs into rotary components, brain matter, and long fiber optic cables. This 
is important because each junction of the light path, such as the rotary component, can 
cause a 50% loss of power. New light-emitting diode (LED) technology has been used 
successfully. Several images in Appendix A show one LED arrangement. The advent of 
LED fiber coupled equipment, with higher numerical aperture fiber, has made it possible 
to use LEDs that are significantly less expensive than a laser setup.  
 Through lasers, genetic engineering, and the technology to use viral vectors, it is 
now possible to produce and control these channels in mammalian brains. Optogenetics 
creates neurons that can be excited or inhibited instantly (50-250 fS) and with great 
precision (Nagel et al., 2003). Since the discovery of ChR2, several other channels have 
been discovered. In general, Channelrhodopsins are excitatory, halorhodopsins silence 
neurons by hyperpolarizing them, and archearhodposin works on similar principles as 
halorhodopsin, but with higher affinity for mammalian neurons (Xue 2012). 
The tools for optogenetic studies keep being refined and new tools are found constantly. 
The ChR2 protein has also had some genetic mutations happen that scientists have 
isolated for different variations. Zhao (2010) made use of the mutation ChR2(H134R). 
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This mutation allows the channel to stay open longer and is more sensitive to lower mWs 
of light. This could benefit behavioral studies, where the effect of neural activation is 
effective, making it easier to distinguish. These light gated ion channels also have an 
EYFP florescent protein attached; this allows confirmation of the existence of these 
channels.  
 Optogenetic tools are often used in conjunction with other genomic technologies, 
a common pairing includes Cre/Lox recombination. Cre/Lox recombination is a site-
specific recombinase technology and is used to delete, insert, translocate, and/or invert at 
specific sites in DNA. This was made possible by researchers that were able to introduce 
bacteriophage recombination systems into mammalian cells, typically a mouse or rat 
(Sauer & Henderson, 1988). The enzyme “Cre recombinase” uses a mechanism that cuts 
one of the DNA strands between two DNA recognition sites (loxP sites), carries out the 
specific recombination event, and then reanneal the strand. Cre inducible viral vector 
technology has been used to insert chanelrhodopsin DNA into sites that also produce the 
enzyme tyrosine hydroxylase (Madisen et al., 2012). This specific targeting system 
effectively expresses chanelrhodopsin on only catecholaminergic neurons (epinephrine, 
norepinephrine, and dopamine). 
 In order to activate ChR2, 470 nm (blue) wavelengths of light must be pulsed 
onto it (Zhang et al., 2010). As mentioned previously, Bass et al. (2003) discovered that 
250 light pulses at 5 Hz directed into the ventral tegmental area of experimental animals 
would increase dopamine in the rat’s nucleus accumbens. The researchers used fast-scan 
cyclic voltammetry to confirm dopamine concentration levels. This data collection tool 
utilizes carbon-fiber microelectrodes to detect dopamine and numerous other 
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neurotransmitter concentrations. The experiment also established that ethanol 
consumption would significantly drop during periods of increased dopamine activity.  
 Researchers have recently used optogenetic tools to delve into general anxiety 
disorder (GAD), which has long been a chronic and recurrent mental health issue with 
high prevalence (Kessler, 2009). Kessler describes GAD as disproportionate worries in 
the lack of urgent threats. GAD has a 28% lifetime prevalence, and a high concordance 
rate with other mental illnesses that display anxiety. Twin studies (Roy, 1995) have 
shown that a significant portion of patients inflicted by GAD also develop major 
depression (MD). A study using functional magnetic resonance imaging (fMRI) 
technology has shown that amygdala activity plays a role in anxiety (Etkin, 2009). The 
study concludes that decreased oxygen levels in the amygdala are correlated with GAD; 
the fMRI finding still lacks more precise details, such as cell type. At Stanford 
University, a study used optogenetics to excite basolateral amygdala glutamate terminals 
in the central terminal of the amygdala. Excitation of these neurons would increase 
anxiety and the inverse action, inhibition of these neurons, would reduce anxiety (Tye et 
al., 2011). Behavioral assessment of animal models in conjunction with optogenetics has 
given researchers a more transparent glimpse into mental health. 
 GAD has been the focus of several animal behavioral assessments. Two such 
assessments used in the previously mentioned study (Tye et all, 2011), are named the 
elevated-plus maze and open-field test. The elevated-plus maze consists of a plus shaped 
raised platform in which two of the arms have high walls. It is believed that rodents will 
spend more time in the exposed area when they are less stressed. A reduction in stress, as 
measured through increased time spent in the open arms of the elevated-plus maze, has 
been demonstrated in rodents who have been given pharmacological agents designed to 
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reduce stress (Fernandes & File, 1996). Scientists knew that these anti-anxiety drugs 
would reduce anxiety in humans, but the mechanism of action remained unknown.  
 Major depressive disorder is characterized as a persistent low mood accompanied 
by loss of pleasure in customarily enjoyable activities. Another way to look at major 
depressive disorder is that an individual with depression is less motivated to escape 
stressors compared to a healthy individual. Lack of motivation has been emulated in 
animal models with the tail suspension test. In the tail suspension test, healthy mice are 
restrained by their tail and will struggle to get away; ‘depressed’ mice will not. The 
causes of depression are complex and multiple brain regions, as well as different classes 
of neurotransmitters, have been linked to the disorder. Optogenetics has been used to 
explore the underlying mechanisms as well as how anti-depressant drugs exert their 
effects.  
 Using a mouse model of depression called chronic social defeat stress and 
optogenetics, researchers determined that excitation of the medial prefrontal cortex 
(medial prefrontal cortex) would produce anti-depressant effects (Covington et al., 2010). 
A mouse was placed in a chamber with another aggressive mouse that caused chronic 
stress. According to Covington, mice subjected to social defeat stress will have decreased 
levels of the immediate early genes, c-fos, and arc; which are known to be cellular 
indicators of clinical depression in humans’ postmortem. Optogenetic stimulation of the 
medial prefrontal cortex would produce strong effects similar to anti-depressant 
compounds and bring IEG levels to normal, without the known side effects of anti-




 Dopaminergic neurons in the ventral tegmental area are crucial for the brains 
reward circuitry, but are also important in depression. Patients with MDD exhibit 
anhedonia, or an inability to enjoy pleasurable activity. Optogenetic tools and the 
aforementioned chronic social defeat stress model have linked activity of specific types 
of neurons in the ventral tegmental area to depression (Chaudhury et al., 2013). 
Chaudhury established that stimulation of dopaminergic neurons in the ventral tegmental 
area would cause an increased susceptibility to social defeat stress and anhedonia, as 
measured through social avoidance and decreased sucrose preference. Furthermore, the 
researchers showed that inhibition of ventral tegmental area projections would induce 
resilience to stressors. These studies reveal novel neural and circuit-specific mechanisms 
of depression. 
 Addiction, clinically known as substance dependence, is a chronic condition that 
grows from repetitive drug intake that results in withdrawal symptoms once drug intake 
ceases. Substances that cause dependence are thought to activate the mesocorticolimbic 
pathway. As already mentioned, the ventral tegmental area in the midbrain extends to the 
nucleus accumbens through the medial forebrain bundle. The ventral tegmental area also 
projects to the prefrontal cortex (PFC), where additional information is integrated into the 
motivated behavior. Food, water, sex, and other pleasurable daily normal activities 
activate this mesocorticolimbic circuit. Simply put, drugs of abuse “hijack” this circuitry 
to cause addiction. Activation of the circuit in response to drugs of abuse can be 
demonstrated in animal models. 
 According to Tzschentke (2007) conditioned place preference is a type of 
Pavlovian conditioning applied to quantify the motivational effects of objects or 
experiences. A research animal is placed into a container that consists of two distinct 
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chambers. Typically, the animal will receive a drug of abuse that has been known to 
produce pleasurable effect in only one of the chambers. In the other chamber, the animal 
receives the vehicle to act as a control. conditioned place preference has been able to 
show repeatedly that the animal will develop a preference for the chamber where they 
receive the drug.  
 Hsing-Chen Tsai (2009) implanted ChR2 into dopaminergic neurons of the 
ventral tegmental area and tested animals performing in a conditioned place preference 
environment. The experimental group of animals was placed in a container that had two 
chambers. The first day of testing, mice received 1 hertz of optical excitation in chamber 
one. The following day, mice received 50-Hz stimulation in chamber two. Mice 
developed a clear preference for the chamber with 50 Hz stimulation (P < 0.001 t test; n = 
13 mice). Mice would prefer a chamber with 1 Hz over no stimulation, but 50 Hz 
produced the strongest preference. These findings sufficiently demonstrated that 















This study was conducted to evaluate locomotor behavior during activation of 
brain regions linked to the positive symptoms of schizophrenia and the actions of 
antipsychotic drugs. This study corroborates with evidence that increased activity in 
mesolimbic dopamine pathways can cause hyperactive locomotion in animals and 
psychosis in humans. The basis of these findings mostly comes from electrophysiology 
and pharmacological techniques. The recent development of optogenetic tools have 
allowed researchers to re-examine the aforementioned notion. The recent development of 
optogenetic tools allow researchers a level of specificity for cell types not previously 
available…As previously mentioned, the ventral tegmental area is comprised of a wide 
diversity of neurons that produce GABA, glutamate, and dopamine. When an area of 
brain is electrically stimulated, all types of neurons are activated. Optogenetic tools 
overcome this wide-spread activation with the use of Cre/Loxp systems, which was also 
previously mentioned. The pairing of these technologies allow for the targeting of 
specific neurotransmitter groups. This study used these technologies to evaluate D2 
receptor antagonism in rats who had mesolimbic and mesocortical dopaminergic neurons 
activated with optogenetic tools. The tools used in this study could make it easier to 
evaluate the involvement of these specific cell types, in regards to behavior and the 
effects of antipsychotic drugs. Questions about the causal mechanisms behind the 
symptoms still remain. This study does not attempt to answer those immense questions, 
instead it is a simple demonstration that light shown onto genetically modified neurons 
elicits a behavioral response. This study builds the foundation for future experiments, 
asking similar questions, to grow upon.  
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 This study used highly spatial and temporally precise tools to investigate how 
neuronal activity can affect locomotor behavior. Video tracking equipment allows us to 
visually track their movements, from where they traveled to their velocity to how close 
they got to the walls, and other behaviors. The expectation is that they’ll be more active 
with increased dopamine activity, to a certain point. There is also a record of body 
temperature, which can increase when dopamine production is elevated. These studies 
will allow us to specifically associate behavioral and physiological effects with activation 
of dopamine neurons and allow us to examine the ability of D2 receptor antagonism to 
reverse these effects or pharmacological enhancement of dopamine release to augment 
these effects. This study took the first steps in using optogenetic tools for evaluating 



















All experiments were performed on adult Male Sprague Dawley rats. 10 wildtype 
animals and 10 Tyrosine Hydroxylase (TH)-Cre animals were purchased from Sage 
Laboratories. Surgical procedures on the animals began when they were between 350-400 
g and were between 10-14 weeks old. Behavioral procedures occurred at least four weeks 
after viral injection. Subjects were housed at 22-24*C with freely–available food and 
water. All procedures were approved by the Northern Michigan University Institutional 
Animal Care and Use Committee (IACUC #257) (see Appendix A). 
 
Stereotactic injection and cannula implantation materials 
 
pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA was a gift 
from Karl Deisseroth (Addgene plasmid # 20298), (Image 9 Appendix B). Anesthesia, 
NMU Biology department’s isoflurane vaporizer to anesthetize mice or rats. Isoflurane is 
volatile and proper ventilation is needed. Nonsteroidal anti-inflammatory drug (NSAID) 
Meloxicam, 1.0 mg per kg, Penicillin G, 30% Bleach in beaker, to dispose materials in 
contact with virus, Lubricant eye ointment, Anti-Septic-Chlorhexidine & Ethanol, C&B 
metabond, Dental cement, ~10-week old WT and TH: Cre rats, Surgical tools. Scissors, 
forceps, and scalpel blades. Small animal stereotactic frame, Cannula Holder (custom 
made by Kale Polkinghorne, Northern Michigan University). Programmable micro 
syringe pump, 10 micro liter Hamilton micro syringe and tubing, Cotton swabs, High-
speed micro drill with charger. 0.5 mm and 0.9 mm Micro drill stainless steel burrs. 1 ml 
Syringes with subcutaneous needles, Surgical suture, Heating blanket, and Epoxy glue. 
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Material for optogenetic stimulation  
 
4 channel PlexBright system driver with Radiant 2.0 and pattern generation. 
Drives LEDs or Lasers; 8 digital inputs and 16 digital outputs. Includes controller, 4 
colored BNC cables, Radiant 2.0 software, USB license key and electronic user guide., 
Dual LED rotary commutator with 2 Magnetically mounted compact LED modules for 
use with commutator, terminating in an LC connector for use with an LC patch cable. 
Blue, 465nm, 300mA max current. 2 200/230µm fibers; LC connector to compact LED 
module; LC ferrule with polished tip; 1 m length with stainless steel jacketing LC-LC 
coupler, Bronze mating sleeves, Refractive gel, and an Optical cleaning kit with cleaning 
solution, lint free wipes, and lens paper. Light Measurement Kit; includes ThorLabs 
PM100D Digital optical power meter with 4-inch LCD display & USB interface; 
ThorLabs S140C integrating sphere photodiode optical power sensor, 350-1100 nm, 1 
µW-500 mW; and Plexon PlexBright adaptor set. 
 
Materials for behavioral assessment 
 
Noldus Ethovision Hardware and XT 7.0 software (Noldus Information 




The locomotor enclosure was a wooden box with four separate identical 
compartments measuring 45.72 cm long x 45.72 cm wide and 27 cm tall. The side walls 
were painted white and a black rubber mat was placed in the bottom to provide a contrast 
in color to better track movement. An infrared thermometer (model # 153IRB, Bioseb, 








Saline, raclopride, and amphetamine were administered subcutanteously. 
intraperitoneally in 1.0 mg/kg, 0.1, or 0.3 mg/kg doses.  Drugs were dissolved in a 
ringer’s solution containing 145 mM NaCl 2.7 mM KCl, 1.0 mM MgCl2, and 1.2 mM 




Proper target coordinates (Paxinos, 1997) were confirmed prior to when the 
experimental animals underwent surgery. Image 1 (Appendix B) was processed and 
collected by Dr. Erich Ottem; he utilized an Olympus Fluoview confocal laser-scanning 
microscope here at Northern Michigan University. This image demonstrated proper 
needle placement in the ventral tegmental area, the visible needle tract aligned with the 
same coordinates described in Image 2 (Appendix B).  
 
Implant Testing and Fabrication 
 
The fiber optic light guides were custom made in-house, following protocols from 
ThorLabs’s Guide to Connectorization and Polishing Optical Fibers, this PDF is freely 
available online (ThorLabs, 2006). After fabrication, all implants were tested to ensure 
proper assembly and that enough light would be emitted. When 50 mWs were pulsed 
from a LED, each implant used during experiments emitted at least 5 mWs. 5 mWs is 
above the activation threshold for ChR2 and this was deemed sufficient for implantation. 
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At this activation strength and wavelength, light was emitted in a cone shape that did not 
extend past the ventral tegmental area (assuming the implantation hit the coordinates). 
 Surgical Procedures 
The procedures to inject 0.5 ul of the viral vector and to implant light guides that 
terminate at the same coordinates were similar to procedures described by Deisseroth 
(2011) and Pehrson et al. (2012). First, all surgical tools were cleaned and sterilized. The 
surgical table was disinfected with 70% ethanol. Aseptic conditions are necessary to 
prevent infection and to guarantee survival for the following weeks. Underneath a sterile 
absorption gauze, a heating pad was placed and kept at 35˚ C. Then the AAV was thawed 
on ice; AAV can be kept at 4 Cº for 1 month. Meloxicam (1.0 mg/kg) and penicillin (0.25 
ml) were given subcutaneously to minimize pain and discomfort, it is important to 
administer one hour before causing pain and to prevent infection. Rats were anesthetized 
using 1.5-2.5% isoflurane. The injection needle was slowly lowered to the proper depth 
(A/P -4.9mm, M/L +2.1mm; D/V -8.6mm; Paxinos et al., 1997) and the virus was 
injected the virus with a microsyringe through an internal cannula at a rate of 0.1 ul/min. 
We waited one additional minute to allow time for the virus to spread, and then slowly 
removed needle. Next, the light guide was placed in the cannula holder and slowly 
lowered into the brain to the same coordinates as the injection needle. Then the skull was 
dried with cotton swabs. After it was dry, a thin layer of C&B metabond was applied to 
the skull and around the cannula pedestal to fix the pedestal in place. Both groups 
(THCre and WT) underwent the surgery and viral injection, in order for the WT rats to 
serve as controls. Follow up injections of 0.5 mg/kg were given every 24 hours for the 






The rats were brought into the behavioral testing room 30 minutes prior to video 
recording; which was comprised of three five-minute long tracking sessions per animal. 
Ten minutes before a recording session, the rat would be connected to the fiber optic 
cable. Each experiment was designed in an A/B/A pattern (baseline/treatment/baseline), 
meaning that the first five-minute session they would receive no light, the second 5-
minute session began with 50 seconds of light pulses from the blue LED diodes, and the 
final five-minutes there was no light. At the end of each 5-minute session, body 
temperature would be recorded. The first experiment was conducted to determine if light 
would produce a significant increase of movement and/or an increase of body 
temperature while the animals received no drugs. The second experiment included 




 The dependent variables measured for the locomotor test were total cm travelled 
and body temperature. A repeated measures one-way analysis of variance was used to 
analyze the effects of light and each drug on each measure. Any significance was 
analyzed further with a Tukey’s multiple comparisons test in order to determine which 
group means were significant from each other. Missing data points were filled in with the 
group mean. All analyses were conducted using GraphPad Prism for Windows Version 






Locomotor Behavior Experiments 
 
Total cm travelled: 5 minute trials 
 
Figure 3 represents the mean path length for 5 minutes before (M = 1506.55, SD 
= 493.56), during (M = 1893.16, SD = 705.12), and after trials of light pulses into the 
transgenic rats. Pulses of light significantly increased path length F (2, 16) = 6.284, p < 
0.01. A significant increase of path length was found between the “during” session 
compared to the “before” or “after” trials. 
 
Figure 4 represents the mean path length in 5 minutes, before (M = 1560.92, SD = 
377.17) and during (M = 1636.35, SD = 502.65) and after trials of light pulses in wild 
type rats. Pulses of light had no significant effect on path length in the wildtype rats, F(2, 
12) = 0.09793, p = 0.9074.  
 
Body Temperature  
 
Figure 5 represents the mean body temperature, which was assessed at the end of 
each locomotor activity trial, for the in transgenic rats. Pulses of light significantly 
increased body temperature F (2, 16) = 21.78, p < 0.01. A significant increase of body 
temperature was found between the “during” session compared to the “before” or “after” 
trials. 
 
Figure 6 represents the mean body temperature for the wild type rats. Pulses of 






Figure 7 represents the mean path length in 5 minutes, before and during trials of 
light pulses in transgenic rats during saline and amphetamine treatments. Amphetamine 
significantly increased path length F (3, 21) = 67, p < 0.01. A significant path length 
increase was found between the “during” session compared to the “before” or “after” 
trials. 
Figure 8 represents the mean body temperaturefor the transgenic rats treated with 
amphetamine. Pulses of light had a significant increase on body temperature F (3, 21) = 




Figure 9 represents the mean path length in 5 minutes, before and during trials of 
light pulses in transgenic rats during saline and raclopride 0.1 mg/kg and 0.3 mg/kg 
treatments. Significant differences across the testing conditions was found, F (5, 30) = 
3.0, P < 0.05. Post hoc results demonstrated that there was significant path length 
increase was found between the means of saline treatments and 0.1 mg/kg raclopride+ 
treatments. There was no significant increase found between saline treatments and 0.3 
mg/kg+. 
Figure 10 represents the mean body temperature for the transgenic rats during 
saline and raclopride 0.1 mg/kg and 0.3 mg/kg treatments. 0.3 mg/kg raclopride treatment 
compared to saline significantly decreased body temperature F (5, 35) = 6.1, p < 0.01. 
Post hoc results showed a significant decrease in body temperature at 0.1 mg/kg 
treatment and a significant increase from 0.1 mg/kg to 0.3 mg/kg.  
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All figures represent the mean plus the standard error of the mean. 
“+” =trial with pulses of light and “*” = significance. 
 
Figure 3: THCre Baseline/Distance Travelled  
 
Figure 3 represents the post hoc results comparing means for the total cm travelled in 5 
minutes, before, during, and after trials of light pulses into the transgenic rats. Treatment 
with light pulses significantly increased the path length *p < 0.05 versus “before” and 
+p<0.05 versus “after.” 
 
Figure 4: Wild Type Control Group/Distance Travelled 
 
Figure 4 represents the mean for the total cm travelled in 5 minutes before, during, and 
after light pulses into the WT rats. Treatment of light pulses into wild type rats had no 








































Figure 5: THCre Baseline/Body Temperature 
 
Figure 5 represents the mean for body temperature before, during, and after trials of light 
pulses into transgenic rats. Treatment with light pulses significantly increased body 




Figure 6: Wild Type Temperature/Control Group 
 
Figure 6 represents the mean for body temperature travelled before, during, and after 
trials of light pulses into wild type rats. Treatment with light pulses had no significant 
























































Figure 7: Amphetamine and Distance Travelled 
 
Figure 7 represents the mean for the total cm travelled in 5 minutes, before, during, and 
after trials of light pulses into saline and amphetamine treated transgenic rats. Treatment 
with amphetamine significantly increased the path length *p < 0.05 versus “Saline” and 
+p<0.05 versus “1.0mg/kg”. 
 
Figure8: Amphetamine and Temperature 
 
Figure 8 represents the mean for body temperature before, during, and after trials of light 
pulses into saline and amphetamine treated transgenic rats. Treatment with light pulses 












































“+” = Light 





Figure 9: Raclopride and Distance Travelled 
 
Figure 9 represents the mean path length in 5 minutes, before and during trials of 
light pulses in transgenic rats during saline and raclopride 0.1 mg/kg and 0.3 mg/kg 
treatments.  
 
Figure 10: Raclopride and Temperature 
 
Figure 10 represents the mean body temperature for the transgenic rats during 



















































































T re a tm en t
“+” = Light 





This study explored the use of optogenetic tools to better understand treatments 
used for schizophrenia. The “positive” symptoms (e.g., hallucinations, paranoia, etc.) of 
schizophrenia may come from overexpression of dopamine in mesolimbic dopamine 
neurons. Positive symptoms can be produced in healthy volunteers treated with 
amphetamine, a psychostimulant drug and dopamine releaser. Conversely, antipsychotic 
drugs may reduce positive symptoms by blocking receptors for dopamine. This study 
used optogenetics to explore how drugs that alter dopamine neurotransmission might 
alter behaviors occurring from activation of mesolimbic dopamine neurons in the ventral 
tegmental area. Light-induced activation of dopaminergic neurons in the ventral 
tegmental area in male rats produced a significant increase in total distance traveled in an 
open field and body temperature. Animals treated with amphetamine, a dopamine 
releaser, also had a significant increase in total distance travelled and body temperature. 
Light-induced activation of dopaminergic neurons during trials of amphetamine did not 
show a significant change, it is logical to think amphetamine depleted neurons of 
dopamine. A D2/3 receptor antagonist did block these effects. These results demonstrate 
that selective activation of mesolimbic dopamine neurons produces effects similar to 
amphetamine. Further, they coincide with previous findings that used different research 
techniques to link amphetamine’s effects to mesolimbic dopamine neurons. This proof of 
concept study was the first to be conducted at Northern Michigan University, and also 
serves as the first to report the effects of an antipsychotic drugs used with optogenetic 
techniques. A significant amount of trial and error managed to successfully implement 
this research tool for future NMU students to utilize.  
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Optogenetic tools have increased locomotor behavior before, optogenetics was 
recently used to selectively activate neurons expressing Calcium/calmodulin-dependent 
protein kinase type II alpha chain (Commonly known as CaMKIIa) in the ventral 
tegmental area of Sprague Dawley rats (Guo et al., 2014). CamKIIa is an enzyme is 
crucial for calcium signaling involved with hippocampal long-term potentiation and 
spatial learning. Guo (2014) demonstrated that excitation with light into the ventral 
tegmental area would increase activity in free roaming tasks. 
Pulses of light significantly increased path length in the transgenic rats. As 
previously shown, increased dopamine concentrations can cause an increase of activity 
within the sympathetic nervous system (Tritsch, Ding, & Sabatini, 2012). The mean for 
the total cm travelled in 5 minutes, before and during. Adding to this increase of 
locomotor behavior, pulses of light significantly increased body temperature. A 
significant increase of body temperature was found between the means of the session 
with light compared to before and after. As mentioned earlier, dopamine antagonists have 
been shown to cause hypothermia (Chaperon et al., 2003). This study demonstrated that 
dopamine plays an intimate role with body temperature regulation. 
The control group was comprised of wild type Sprague Dawley rats that were 
bred and raised from the same strain as the transgenic rats and in the same location. As 
expected, Pulses of light had no significant effect on path length. 
In five minute trials of the testing sessions, amphetamine at a 1.0 mg/kg dose 
produced a significant increase of distance travelled compared to baseline data. These 
results are comparable to previous experiments (Westerink et al., 2001) (Griffith et al., 
1972) (Lieberman et al., 1987) (Laruelle et al., 1996).   
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 This study raises several intriguing research questions, such as what would occur 
when a treatment of a D1 receptor antagonist treatment is implemented? Or an atypical 5-
HT receptor antagonist? What would these drugs do to activity? The addition of 
electrophysiological. Fast-scan cyclic voltammetry, or microdialysis equipment would be 
immensely helpful in answering more detailed questions. Optogenetics is commonly 
paired with these technologies and allow researchers to more thoroughly understand 
neuronal communications. As previously mentioned, fast-scan cyclic voltammetry could 
report specific neurotransmitter concentrations in regions connected to a region that is 
being activated with optogenetics.  
Optogenetics has been used in a variety of animals, rodents mostly, but also 
zebrafish (Douglass et all, 2008), fruit flies (Drosophila melanogaster) (Lima & 
Miesenböck, 2005), nematode worms (Caenorhabditis elegans) (Blaxter, 2010) and non-
human primates (Han et al., 2011). With a research tool as powerful as optogenetics, the 
logical next step is producing it in humans for therapeutic effects on mental illnesses. 
Chow and Boyden (2013) recently published an article with a discussion of obstacles that 
would have to be overcome to bring optogenetics to clinical trials. The largest issue is the 
use of viral vectors and the subsequent immune response (Chow & Boyden, 2013). 
Human opsins, such as rhodopsin in the human eye, could be inserted into neurons, but 
these cells are slower than the microbial ones currently in use for optogenetics. Gene 
therapy is advancing every day and it is possible that someday humans could reap the 
benefits of the precision actions optogenetics has to offer.  
 Even if optogenetics remains as purely a research tool and does not give rise to 
beneficial effects directly in our species, it has still offered humans an unparalleled look 
into the function and dysfunction of the nervous system. Optogenetics has been adopted 
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in laboratories around the world and has enabled scientists to increase or decrease the 
activity of exclusive brain regions on command. Great insight has been obtained through 
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This image demonstrates the coordinates were in a dopamine rich ventral tegmental area. 
The green color in the image is a florescent marker bound to tyrosine hydroxylase. The 
blue color is named 4’,6-diamidino-2-phenylindole (DAPI), it is a florescent DNA-
binding protein that stains cellular nuclei. This effectively illuminates where the DNA, 
nucleus, and cell body of neurons exist. The large black path in the center is the tract left 












Image 3 shows the light testing equipment in action, each implant passed the minimum 





























Image 8 Full Sequence Map for pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-
WPRE-HGHpA. This was a gift from Karl Deisseroth (Addgene plasmid # 20298). Map 
generated by Addgene from full sequence supplied by Karl Deisseroth. 
 
Image 9  
 
Image 9 shows individual data points during the final series of raclopride.  
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